NY-AIRTAME
15.1.2020 14:02:12 CET | Business Wire | Press release
Airtame, the leading wireless screen sharing and collaboration platform, today announced the official launch of Airtame Cloud, a new software-as-a-service product designed to make screens smarter. The open platform offers device management and access to a range of digital signage solutions, helping users create smarter offices, workplaces and schools with their screens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200115005060/en/
Airtame Cloud -- which has been available in beta for over a year, and is already used by 6,500 organizations globally -- is a unified platform that enables users to manage and update their screens remotely. It was built on an open ecosystem that seamlessly integrates with a range of applications that can be used to create tailored digital signage, such as Google Slides, Microsoft OneDrive, Trello, Dropbox, and YouTube, with more integrations to come.
Cloud will allow users to:
- Manage screens remotely, freeing up IT administrators to change settings and conduct bulk updates with cloud access to Airtame-enabled screens
- Boost productivity and engagement, with personalized digital signage in meeting rooms, classrooms and common areas
- Save on power, by scheduling screens to turn on and off according to office or school hours
- Avoid blank screens , by scheduling imagery and videos to play on loop
The launch of Cloud marks the evolution of Airtame as it continues to grow from a hardware to solution-centric business, with a strong focus on facilitating smart offices and schools around the world.
“With Airtame Cloud, we’re providing a solution that empowers our customers to boost engagement and productivity for employees, students and visitors, whether that be in the office, meeting room or classroom,” said Airtame Co-Founder and Co-CEO Jonas Gyalokay.
“Part of our vision at Airtame is to help enterprises and schools create smarter offices and classrooms. While this starts with screens, we imagine one day it could extend to all aspects of the workplace or classroom, with the potential to automate lighting, sound, room temperature and more.
“With the evolution of IoT, the possibilities to connect devices and screens are endless. As a starting point, Airtame Cloud will help schools and enterprises reduce their energy consumption by automating screens to turn off when they’re not being used. We’re looking forward to embracing technology to build additional hardware and software features of this kind in the future.”
Airtame Cloud will launch with two plans: Airtame Cloud Lite, a free version of the product that offers the essential features needed to manage and update Airtame devices, and Airtame Cloud Plus, a premium version that enables digital signage and additional features needed to create a smart office or classroom.
The launch follows a series of important milestones for Airtame, including the recent announcement of its industry-first partnership with Airserver. The company has enjoyed 100% YoY growth since its market launch in 2014.
ENDS
Access the full press kit containing imagery and video materials here .
ABOUT AIRTAME:
Airtame offers a wireless screen sharing and collaboration platform that allows users to instantly display content from any personal device to any shared screen. The platform is used to promote interactivity and collaboration in meetings, presentations and classroom settings, as well as for digital signage in retail stores, corporate environments, conference facilities, hotels, and other venues. Airtame was launched in 2014 and has grown into a company with 100+ people, and with offices in New York, Los Angeles, Copenhagen, and Budapest.
To learn more, visit www.airtame.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom